Clinical Trial

Metabolic Effects of Angiotensin-(1-7)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2015-12-31; most recent amendment 2026-05-18.
Status change: Active, Not Recruiting → Recruiting 2016-02-03
Trial Details
NCT Number NCT02646475
Lead Sponsor Vanderbilt University
Conditions Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Enrollment 26 participants
Start Date 2016-02
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22